Novo Nordisk has officially launched Ozempic (injectable semaglutide) in India. The once-weekly therapy is approved as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes mellitus (T2DM).
The launch comes at a critical time for India’s growing diabetes burden.
Why Ozempic’s Entry Matters for India?
India is facing a rapidly escalating metabolic health crisis.
According to WHO estimates (2023–24):
- 101 million people in India are living with diabetes
- 136 million have prediabetes
- 254 million are affected by generalised obesity
This makes India the second-largest diabetes-affected country globally, after China. Effective, evidence-backed therapies are no longer optional. They are essential.
What Ozempic Offers Clinically?
Ozempic is a GLP-1 receptor agonist (GLP-1 RA) designed to address multiple aspects of diabetes management.
Key clinical benefits include:
- Significant HbA1c reduction, even in patients with HbA1c ≥7%
- Meaningful weight loss, supporting better metabolic health
- Reduced cardiovascular risk, especially in patients with existing heart disease
- Protection against chronic kidney disease progression, a major long-term concern in T2DM
This makes Ozempic suitable for patients with:
- Long-standing diabetes
- High cardiovascular risk
- Established cardiovascular disease
How Ozempic Works?
Ozempic acts on multiple pathways involved in diabetes and obesity:
- Improves glycaemic control by lowering blood glucose
- Regulates appetite by acting on hunger centres in the brain
- Supports sustained weight loss
- Reduces risks of cardiovascular and kidney complications
All of this is delivered through a once-weekly injection, reducing treatment burden.
Dosing and Availability in India
Ozempic is now available in India in:
- 0.25 mg
- 0.5 mg
- 1 mg
It is delivered via the FlexTouch Pen, designed for ease of use and physician-guided dose titration.
What Novo Nordisk Says?
Vikrant Shrotriya, Managing Director, Novo Nordisk India, said the launch marks a major milestone for diabetes care in the country.
Ozempic combines:
- Proven global clinical performance
- World-class manufacturing quality
- A robust and reliable supply chain
The goal, he said, is to offer Indian patients better glycaemic control, weight management, and long-term heart and kidney protection through a simple weekly therapy.
Backed by Long-Term Evidence
Ozempic is not new to global markets.
Key credentials include:
- Over 20 years of research and development
- More than 38 million patient-years of global clinical use
- Inclusion of semaglutide in WHO’s Model List of Essential Medicines
This positions Ozempic as one of the most trusted GLP-1 therapies worldwide.
The Bigger Picture
With Ozempic’s launch, India gains access to a globally established therapy that targets diabetes beyond glucose control.
- For physicians, it offers flexibility.
- For patients, it reduces treatment complexity.
- For the healthcare system, it supports better long-term outcomes.
In a country where diabetes and obesity are accelerating fast, this launch is more than a product update. It is a strategic step toward modern diabetes care.
